Table: Nxera Pharma -2024 parent results
Feb 14 (Reuters)-
Nxera Pharma Co., Ltd.
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Dec 31, 2024 Dec 31, 2023 Dec 31, 2025 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECAST H1 FORECAST
Sales 6.58 5.02
(+31.2 pct) (+348.4 pct)
Operating loss 4.62 loss 335 mln
Recurring loss 1.55 loss 3.30
Net 2.14 loss 3.29
EPS 23.89 yen loss 39.81 yen
EPS Diluted 19.63 yen
Ann Div NIL NIL NIL
-Q2 Div NIL NIL NIL
-Q4 Div NIL NIL NIL
NOTE - Nxera Pharma Co., Ltd..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4565.T
Recent news on Nxera Pharma
See all newsNxera Pharma Submits Marketing Authorization Application For Vamorolone In South Korea For Treatment Of Duchenne Muscular Dystrophy
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Nxera Pharma - Entered Into Exclusive License, Supply And Commercialization Agreement With Synmosa For Quviviq Across Eight Asia-Pacific Markets
Brief: Nxera Announces Successful Resolution Of Minig Patent Infringement Action
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up